288 CF patients with totally implantable venous access devices (TIVAD): prospective survey of Doppler-US (DUS) central venous thrombosis (CVT) and thrombophilia (TB) assessment  by Munck, A. et al.
S130 10. Delivery of Care Posters
286 The use of continuous infusions of subcutaneous terbutaline in
adult patients with cystic ﬁbrosis
G.H. Jones1, D. Nazareth1, S.M.H. Kazmi1, J. Gallagher1, J. Greenwood1,
M. Ledson1, M. Walshaw1. 1Liverpool Adult CF Unit, Liverpool, United Kingdom
Introduction: Although a continuous subcutaneous infusion of terbutaline (CSIT)
can be useful in treating bronchospasm [1] there are no studies looking at its use in
adult CF, where many patients can develop this complication during a pulmonary
exacerbation. We frequently use CSIT for this purpose, and wished to assess its
tolerability.
Method: We asked 24 patients their views on CSIT following its use during an
inpatient stay.
Results: There were 93 prescriptions of CSIT over 16 months, over 70% com-
menced within 72 h of admission. Median dose was 5mg/24 h (range 2.5−10);
mean duration of therapy was 11 days (2−36). Most patients felt that CSIT was
useful (17/24), not uncomfortable (20/24) and helped them to improve more quickly
(14/24). Those who had also experienced intravenous aminophylline rated CSIT
more effective (10/16) with only 2/16 considering it to cause more side-effects;
all patients appreciated the greater mobility afforded by CSIT. Tremor (11/24),
palpitations (3/24) and headache (2/24) were the most frequent side-effects but were
only considered severe by 2 patients. Adverse effects necessitating dose reduction
were uncommon (5/93) and all such cases tolerated the lower dose.
Conclusions: Our ﬁndings suggest that CSIT is well tolerated and preferred to
intravenous aminophylline by CF patients, with less side-effects and less impact on
mobility. We encourage other centres to consider it as an adjunct to therapy.
Reference(s)
[1] Jones GH, Scott S. Continuous infusions of terbutaline in asthma − a review.
J Asthma 2011; 48(8): 753−6.
287 Experience with a new totally implantable venous access device
G.H. Jones1, J. Gallagher1, S.M.H. Kazmi1, M. Ledson1, M. Walshaw1, J. Greenwood1.
1Liverpool Adult CF Unit, Liverpool, United Kingdom
Background: Totally implantable venous access devices (TIVADs) have revolutionised
the delivery of IV therapy in CF, but they have a signiﬁcant long term complication
rate (line infection/obstruction) of up to 54% [1], necessitating port removal and
delaying treatment. New TIVAD chamber designs aim to reduce these complications
by streamlining outlets and maximising ﬂow, and we wished to assess their efﬁcacy
for our patients.
Method: We compared the complication rate using such a new TIVAD design
(Vortex LP [Angiodynamics®, Cambridge, UK]) in 20 patients over a 22 month period
with that in our existing TIVAD population over the preceding 18 months.
Results: See the table.
Table: Comparison of complication rates
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Old system (76 pts over 18 months) 7 13 1 3 1.75%
New system (20 pts over 22 months) 0 0 1 0 0.23%
Conclusions: The complication rate using this new TIVAD design seems to be less
than with previous devices. We encourage other centres to consider the use of Vortex
TIVADs which has helped us to further decrease our complication rate.
Reference(s)
[1] Royle TJ, Davies RE, Gannon MX. Totally implantable venous access devices − 20 years’ expe-
rience of implantation in cystic ﬁbrosis patients. Ann R Coll Surg Engl. 2008 Nov;90(8):679−84
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A TB tendency has been reported in CF patients (P).
Aims: In P with TIVAD
1. To document the prevalence (Pr) and incidence (In) of CVT detected by DUS
in a multicenter prospective study.
2. To assess genetic and acquired TB proﬁles, hypercoagulability (HC) state.
3. To provide recommendations on TB screening when TIVAD is considered.
Patients and Method: P have been selected at TIVAD insertion (V0). A DUS was
scheduled 1 and 6mo later (V1, V2) and at V0 in case of a previous central line.
TB and HC were evaluated at V0 and at V1 and V2 for acquired TB and HC.
Results: One hundred P (28 CF centres, median age: 20 y) received a TIVAD,
90 completed the 6mo study. In the 44 P who had previously a TIVAD, DUS at V0
identiﬁed a CVT in 4 P. During the study period, CVT were reported in 2 different P.
CVT Pr and In were 6.6% and 2.2%. Pr of TB abnormalities and HC state have
reached 17% and 38% and 5 cases combined abnormalities. Among the P with a
CVT (4 adults, 2 children), an abnormality was detected in 3 adults; TIVAD has not
been removed, anticoagulant therapy (ACT) allowed an uneventful clinical course
(17−31mo).
Discussion and Conclusion: Despite a high In of TB and HC abnormalities,
we found an unpredictable low Pr of asymptomatic CVT (6.6%, 0.12/1000 days),
hampering statistical analysis. Our data do not support a biological screen at time
of TIVAD insertion in terms of cost and beneﬁt but emphasize the relevance of
(1) collecting personal data on VT, (2) assessing prospectively DUS in order to
select P who may take advantage of a biological screen and possibly of an ACT
and (3) the need for further prospective longitudinal cohort assessment.
Supported by VLM (RC O416)
289 The use of alteplase in patients’ portacaths following transfer
from paediatric to the adult unit
J.C. Milnes1, A. Bowling1. 1University Hospital of South Manchester, Adult Cystic
Fibrosis Unit, Mnchester, United Kingdom
Objective: Paediatric CF patients transferred to our Adult unit, who had a venous
implantable access device (portacath) were found to have never bled back or had
then stopped, prior to transfer. Our practice is to use alteplase, 2mg, on patients
whose port doesn’t bleed back. Alteplase is a plasminogen activator which cleaves
plasminogen resulting in the formation of plasmin, which is the enzyme responsible
for clot dissolution. We set out to evaluate the effectiveness of using alteplase on
portacaths, on patients who were transferred to our care.
Method: Patients with an existing portacath transferred from the Paediatric unit
from March 2008 were identiﬁed. It was established if their port had bled back
on transfer or never bled, if alteplase had been administered following transfer, if
the port had bled following and if further doses were necessary: 18 patients were
transferred with an existing portacath, 6 bled back on transfer, 2 patients’ ports
did not bleed, but had not been admitted since transfer, so were excluded, 9 of the
10 patients whose ports did not bleed had alteplase administered, 7 bled back
(77.7%), 2 continued not to bleed (22.2%). One of the ports which didn’t bleed,
had alteplase used as it was very stiff to ﬂush and this problem was resolved. One
port needed alteplase insertion on each of the four subsequent admissions and one
on each of the three subsequent admissions.
Conclusion: The use of alteplase in portacaths that do not bleed should be given
serious consideration in both paediatric and adult areas. The function of being
able to withdraw blood from a portacath instead of venepuncture is much more
favourable and less traumatic for CF patients.
